Back
Full-text
Journal article

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.

  • Steiner M Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
  • Neri D
  • 2011-10-18
Published in:
  • Clinical cancer research : an official journal of the American Association for Cancer Research. - 2011
Antibodies, Monoclonal
Combined Modality Therapy
Humans
Molecular Targeted Therapy
Neoplasms
Radiation Tolerance
Radioimmunotherapy
Radioisotopes
English When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible. Monoclonal antibodies and their fragments, labeled with therapeutic radionuclides, have been used for many years in the development of anticancer strategies, with the aim of concentrating radioactivity at the tumor site and sparing normal tissues. This review surveys important milestones in the development and clinical implementation of radioimmunotherapy and critically examines new trends for the antibody-mediated targeted delivery of radionuclides to sites of cancer.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/40607
Statistics
Document views: 26 File downloads:
  • fulltext.pdf: 0